IBRNvsETF 2ETF Comparison
VS
ETF 2
Choose a second ETF to run a side-by-side ETF comparison with IBRN, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBRN performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/16/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBRN ETF 2 | +8.13%– | +7.48%– | +15.72%– | +65.41%– | +53.34%– | n/a– |
| Flows | IBRN ETF 2 | -– | -– | -– | -– | -$1M– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBRN ETF 2 | +24.90%– | +25.47%– | +24.93%– | n/a– |
| Max drawdown | IBRN ETF 2 | -7.24%– | -8.68%– | -34.98%– | n/a– |
| Max drawdown duration | IBRN ETF 2 | 7d– | 75d– | 338d– | n/a– |
Trading data
IBRN | ETF 2 | |
Last sale 7/17/2026 at 1:30 PM | $37.87 | – |
| Previous close 07/16/2026 | $37.37 | – |
| Consolidated volume 07/16/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBRN | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/17/2026 at 1:30 PM
Live
Closed
IBRN | ETF 2 | |
|---|---|---|
| Last price | $37.87 | – |
| 1D performance | +1.33% | – |
| AuM | $5.61 M | – |
| E/R | 0.47% | – |
Characteristics
IBRN | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | iShares | – |
| Benchmark | NYSE FactSet Global Neuro Biopharma and MedTech Index | – |
| N° of holdings | 74 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 24, 2022 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
IBRN
USA
69.76%
Other
30.24%
ETF 2
Sectors
IBRN
Healthcare
99.84%
Other
0.16%
ETF 2
Diversification
IBRN
Total weight of top 15 holdings out of 15
59.72%
ETF 2
–
Top 15 holdings
Data as of May 31, 2026
IBRN
Alkermes Plc
5.05%
Axsome Therapeutics, Inc.
4.96%
Xenon Pharmaceuticals, Inc.
4.50%
Arrowhead Pharmaceuticals, Inc.
4.47%
Neurocrine Biosciences, Inc.
4.26%
PTC Therapeutics, Inc.
4.03%
argenx SE
3.99%
Praxis Precision Medicines, Inc.
3.86%
Centessa Pharmaceuticals Plc
3.83%
Scholar Rock Holding Corp.
3.73%
Biogen, Inc.
3.66%
Catalyst Pharmaceuticals, Inc.
3.51%
Dianthus Therapeutics, Inc.
3.45%
ACADIA Pharmaceuticals, Inc.
3.35%
Denali Therapeutics, Inc.
3.05%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
